The clinical effectiveness of insulin glargine in patients with type I diabetes in Brazil: findings and implications

Descrição

Tipo

Artigo de periódico

Título alternativo

Primeiro orientador

Membros da banca

Resumo

Aim: Published studies have challenged the cost–effectiveness of insulin glargine versus neutral protamine hagedorn (NPH) insulins in Brazil with limited evidence of increased effectiveness despite considerably higher acquisition costs. However, still a controversy. Consequently, there is a need to address this. Materials & methods: Retrospective cohort study of Type I diabetes patients receiving insulin glargine in Brazil following NPH insulin who met the criteria. Results: 580 patients were enrolled. HbA1c varied from 8.80 ± 1.98% in NPH insulin users to 8.54 ± 1.88% after insulin glargine for 6 months, which is not clinically significant. Frequency of glycemic control varied from 22.6% with NPH insulin to 26.2% with insulin glargine. No statistically significant difference was observed between controlled and still uncontrolled groups for all analyzed factors including type and frequency of insulin use and carbohydrate counting. Conclusion: Limited differences between NPH insulins and insulin analogs in routine clinical care do not justify an appreciable cost difference.

Abstract

Assunto

Medicamentos, Diabetes

Palavras-chave

Brasil, Pesquisa de eficácia comparativa, Insulina glargina, Estudos longitudinais, Insulina NPH, Diabetes tipo I

Citação

Curso

Endereço externo

https://becarispublishing.com/doi/10.2217/cer-2016-0099

Avaliação

Revisão

Suplementado Por

Referenciado Por